Short Interest in CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Decreases By 42.2%

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 331,000 shares, a drop of 42.2% from the January 31st total of 572,600 shares. Based on an average daily trading volume, of 626,400 shares, the days-to-cover ratio is presently 0.5 days. Approximately 28.1% of the company’s shares are short sold.

Insider Buying and Selling

In other CERo Therapeutics news, major shareholder Bioventures Opportunities G. Yk sold 8,505 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $11.00, for a total value of $93,555.00. Following the completion of the sale, the insider now directly owns 205,333 shares of the company’s stock, valued at $2,258,663. This trade represents a 3.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders have sold 64,300 shares of company stock worth $529,409. 18.00% of the stock is owned by corporate insiders.

Institutional Trading of CERo Therapeutics

An institutional investor recently raised its position in CERo Therapeutics stock. ARCH Venture Management LLC boosted its holdings in shares of CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) by 550.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,393,561 shares of the company’s stock after acquiring an additional 7,949,265 shares during the quarter. CERo Therapeutics comprises 0.2% of ARCH Venture Management LLC’s holdings, making the stock its 9th largest holding. ARCH Venture Management LLC owned approximately 626.24% of CERo Therapeutics worth $564,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 29.64% of the company’s stock.

CERo Therapeutics Stock Up 3.7 %

Shares of CERO stock opened at $1.67 on Friday. The firm’s 50-day moving average is $3.03 and its two-hundred day moving average is $8.95. CERo Therapeutics has a 12 month low of $1.50 and a 12 month high of $1,095.00.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.